There is growing interest in assessing multistep carcinogenesis and predicting its course using different molecular markers. TP53 is a tumor suppressor gene and appears to be one of the molecular targets of tobacco-related carcinogens in oral cancer. The present study evaluated the role of p53 expression in patients with leukoplakia and carcinoma of the tongue. p53 expression was studied by immunohistochemistry. All patients with leukoplakia of the tongue were male tobacco users. Nuclear staining of p53 was observed in 79% of those patients. Fifty percent, 25% and 4% of the patients expressed 1+, 2+ and 3+ nuclear staining, respectively. When leukoplakia patients were graded according to histopathology, 67% had hyperplasia and 33% had dysplasia. Nuclear p53 accumulation was 88% in hyperplasia and 62% in dysplasia. In patients with tongue cancer, nuclear accumulation of p53 was seen in only 19% of the tumors, with a staining intensity of 1+ in 13%, 2+ in 2% and 3+ in 4% of the tumors. The prevalence of nuclear p53 positivity (79%) was significantly higher in patients with leukoplakia than in patients with tongue cancer (19%; χ χ 2 = 34.32, r = -0.45, df = 1, p =  0.0001; odds ratio (OR) = 16.66, 95% CI, 5.25-52.86) . Therefore, leukoplakia patients who show p53 expression have a higher risk of developing tongue cancer than those who do not show p53 expression. As the percentage of positivity of nuclear p53 was very low, none of the clinicopathological parameters or disease status showed any significant association with it. The interesting finding is that none of the female cancer patients showed nuclear p53 expression. Therefore, p53 accumulation is believed to be an early event in neoplastic progression of the tongue. (Int J Biol Markers 2006; 21: 74-80)
INTRODUCTION
A number of investigators have observed p53 protein accumulation in malignant tumors as well as during tumorigenesis, unrelated to TP53 mutations. Carcinoma of the tongue is one of the most common head and neck carcinomas. The five-year survival rate for this disease (~50%) has improved only marginally over the past decade. The majority of the patient population present with an advanced stage of the disease at diagnosis. If tongue cancer could be detected at the incipient stage and its advance halted, this would enable a reduction in the mortality associated with the disease. Leukoplakia, the most common premalignant lesion, harbors histological features of hyperplasia and/or dysplasia and is a frequent precursor of squamous cell carcinoma of the tongue. The rate of malignant transformation associated with advanced oral premalignant lesions was reported to be 11% to 36% (1) .
Biomarkers are important molecular signposts of the physiological state of a cell at a specific time. Active genes and their respective protein products made by the cell create these signposts. As a normal cell progresses through the complex process of transformation to a cancerous state, biomarkers could prove vital for the identification of early stages in tongue carcinogenesis and of people at risk of developing tongue cancer. TP53 is a tumor suppressor gene that codes for a phosphoprotein involved in cell cycle regulation and apoptosis. It appears to be one of the molecular targets of tobacco-related carcinogens in oral cancer (2) . Studies performed up to now suggest that TP53 is involved in oral carcinogenesis and that its alteration occurs in this process (3) (4) (5) (6) (7) (8) .
In the present study we have investigated the expression of p53 in patients with leukoplakia and carcinoma of the tongue, thereby identifying patients with leukoplakia who are at risk for developing tongue cancer. Further, in patients with tongue cancer, the expression of p53 was correlated with established clinicopathological prognosticators and survival.
MATERIALS AND METHODS

Patients
Seventy patients with tongue cancer (stage I, T1 N0 M0, and stage II, T2 N0 M0, n=18; stage III, T3 N0 M0 and T1-3 N1-2 M0, and stage IV, T4 N0-3 M0, n=52) and 24 patients with leukoplakia of the tongue (16 cases of hyperplasia and 8 cases of dysplasia of which four mild, three moderate and one severe) were enrolled in this study. These patients were treated at the Gujarat Cancer and Research Institute, Ahmedabad, India, between 1986 and 1990. A detailed clinical history of all patients was obtained from the case files maintained at the institute. The disease was staged according to the UICC TNM classification (9) . The tumors were histologically graded based on the criteria of Broders (10) . The Speciality Clinic of Surgical Oncology performed the surgical procedures. The Radiation Oncology and Medical Oncology units instituted radiotherapy and chemotherapy, respectively. Patients with early stage disease were followed for a minimum period of five years, and patients with locally advanced disease for a minimum period of three years or until their death within that period. Relapse-free survival (RFS) was evaluated only for early stage patients. Overall survival (OS) was evaluated for both early stage (for five years) and locally advanced stage (for three years) patients. For leukoplakia patients it was not possible to discover whether they progressed to squamous cell carcinoma because the majority of these patients were lost to follow-up after receiving treatment. The patient and tumor characteristics are shown in Table II .
Immunohistochemical localization of p53
For immunohistochemical localization of p53 in the 24 leukoplakia samples and 70 carcinoma samples, formalinfixed paraffin-embedded tissue blocks were obtained from the archives of the department of pathology of our institute. This was done using the avidin-biotin peroxidase complex technique as described previously (11) . Primary antibodies and dilutions used in the study are shown below. The primary antibody used was p53 (monoclonal, clone DO-7, DAKO, Denmark) at a dilution of 1:50.
Positive control for p53 included breast carcinoma tissues known to express the respective antigen. Negative control included sections of tongue tumor tissues incubated overnight in the respective blocking sera instead of the primary antibody.
Two independent observers familiar with immunohistopathology who were unaware of the clinical outcome scored all the sections. The staining pattern was classified as nuclear when the immunoreactivity was present in the nucleus of neoplastic cells. The tumors were scored using a semiquantitative score ranging from negative (no staining) to 3+ (1+ for staining in <10% of cells; 2+ for staining in 10-50% of cells and 3+ for staining in >50% of cells). For statistical evaluation the scores 1+, 2+ and 3+ were combined in the positive group.
Statistical analysis
The data were statistically analyzed using SPSS statistical software (12) . The two-tailed chi-square test was used to assess the association between two parameters. Correlation between two parameters was calculated using Spearman's correlation coefficient (r) method. RFS and OS were evaluated using the Kaplan-Meier method. The log-rank test was used to assess the prognostic significance of RFS and OS. Multivariate analysis was done using the Cox forward stepwise regression model. P values less than 0.05 were considered significant.
RESULTS
Both in leukoplakia and carcinoma tissues, staining of nuclear p53 protein was seen in basal and parabasal cells.
Immunohistochemical localization of p53 in leukoplakia
All of the patients with leukoplakia of the tongue were males and were tobacco users. Nuclear staining of p53 was observed in 79% (19/24) of these patients (Tab. I; Fig. 1 ). Fifty percent (12/24), 25% (6/24) and 4% (1/24) of the patients expressed 1+, 2+ and 3+ nuclear staining, respectively.
Among leukoplakia patients graded according to histopathology, 67% (16/24) had hyperplasia and 33% (8/24) had dysplasia. In patients with hyperplasia, the percentage of positive nuclear accumulation of p53 was 88% (14/16). In patients with dysplasia the nuclear accumulation of p53 was 62% (5/8). In patients with dysplasia 50% (4/8), 38% (3/8) and 12% (1/8) had mild, moderate and severe dysplasia, respectively. Fifty percent (2/4) of the patients with mild dysplasia, 66% (2/3) of the patients with moderate dysplasia, and 100% (1/1) of the patients with severe dysplasia showed p53 expression. The nuclear accumulation of p53 was higher in hyperplasia than in dysplasia; however, the difference was not statistically significant (Tab. I).
Immunohistochemical localization of p53 in tongue carcinoma
Nuclear accumulation of p53 was seen in only 19% (13/70) of the patients with tongue carcinoma with a staining intensity of 1+ in 13% (9/70), 2+ in 2% (1/70) and 3+ in 4% (3/70) of the tumors (Tab. I; Fig. 2 ). The prevalence of nuclear p53 positivity (79%) was significantly higher in patients with leukoplakia than in patients with tongue cancer (19%; χ 2 = 34.32, r = -0.45, df = 1, p = 0.0001; OR = 16.66, 95% CI, 5.25-52.86; Tab. I). Therefore, leukoplakia patients who show p53 expression have a higher risk of developing tongue cancer than those who do not show p53 expression.
Relationship of p53 with clinicopathological parameters in patients with tongue cancer
The prevalence of nuclear p53 positivity (19%) was very low, therefore none of the parameters showed a significant association (Tab. II). The interesting finding is that none of the female patients showed nuclear p53 expression; however, all of them had advanced stage disease.
Relationship of p53 with disease outcome
Univariate survival analysis showed no association with overall survival in the entire series of patients with tongue cancer and in patients grouped according to disease stage, as the p53 positivity was only 19%. However, in a small group of early stage patients (n=18), 50% (2/4) of the patients with p53 expression relapsed within five years, while 21% (3/14) of the patients with negative p53 relapsed within five years; the difference was not statistically significant (Tab. III).
DISCUSSION
There is growing interest in assessing multistep carcinogenesis and predicting its course using different molecular markers. The primary purpose of this study was to evaluate the role of p53 expression in patients with leukoplakia and carcinoma of the tongue.
In men, a much greater occurrence of leukoplakia and carcinoma of the tongue was found than in women, Negative  2  12  3  38  2  50  1  34  0  0  57  81  Positive 1+  8  50  4  50  2  50  1  33  1  100  9  13  2+  6  38  0  0  0  00  0  0  0  0  1  2  3+  0  0  1  12  0  00  1  33  0  0  3 due to tobacco and alcohol abuse. This is in contrast to most of the published reports, because women of Gujarat consume less tobacco than those in other parts of the country. Nuclear accumulation of p53 was seen in 79% of patients with leukoplakia. These patients when graded according to their histopathology, 88% of those with hyperplasia and 62% of those with dysplasia exhibited nuclear accumulation of p53. However, these results are in accordance with those of very few studies (13) (14) (15) (16) (17) and contradict the results of many others (5, (18) (19) (20) . The higher prevalence of p53 accumulation in hyperplasia might be a result of wild-type p53 induced by tobacco carcinogens, which confirms the hypothesis that following DNA damage the increase in p53 protein leads to an arrest of cell division in the G1 phase. This arrest allows the activation of a DNA repair system (21) . In some cases, DNA repair is not efficient and a sufficient level of wild-type p53 protein may induce apoptosis (21) . Accumulation of p53 proteins in normal cells followed by certain stresses, such as UV radiation (22) and exposure to carcinogens (23) , was also reported.
In tongue cancer we observed nuclear accumulation of p53 in only 19% of the patients. The prevalence of nuclear p53 expression decreased from hyperplasia to dysplasia and from dysplasia to invasive carcinoma. The risk estimate between leukoplakia and carcinoma in relation to p53 was approximately 16.0, which suggested that leukoplakia patients with p53 positivity had a higher risk of developing tongue cancer. In the present study it was not possible to discover whether the leukoplakia patients progressed to squamous cell carcinoma because the majority of these patients were lost to follow-up after receiving treatment.
In oral squamous cell carcinomas, p53 expression was reported with a range from 11% to 94% (5, 14, 17, 18, (24) (25) (26) (27) (28) (29) (30) (31) including the Indian patient population (5, 19, 26) . Few studies have reported a lack of p53 expression in oral cancer (24, (27) (28) (29) (30) (31) , which was also associated with tumor relapse (30, 31) . In the Indian patient population, Kaur et al (5) have observed a lower incidence of p53 expression in tongue dysplasia (57%, 4/7) and tongue carcinoma (60%; 3/5) as compared with premalignant lesions (70%, 7/10) and carcinoma of the buccal mucosa (92%, 12/13). In a study with a hamster oral cancer model, p53 expression was significantly reduced in tongue dysplastic mucosa and squamous cell carcinoma as compared with preneoplastic lesions and squamous cell carcinoma of buccal mucosa. Moreover, PCNA expression was higher in tongue dysplastic mucosa and squamous cell carcinoma as compared with preneoplastic lesions and squamous cell carcinoma of the buccal mucosa. Hence, it was reported that oral carcinomas of different anatomical sites could exhibit differences in growth, oncogene expression and apoptosis (32) . Several studies of tongue cancer have reported p53 expression in the range of 33% to 54% (28, (33) (34) (35) , which was low in comparison with that in other anatomic sites of the oral cavity. Also, the p53 expression was found to be lower in advanced stage as compared with early stage tongue cancer (33, 35) . In our study, p53 expression was seen in only 19% of patients with tongue cancer, while 74% (52/70) of the patients had advanced stage disease. The low frequency of p53 expression in tongue carcinoma could be due to hypermethylation of the TP53 gene, deletion of both alleles or unstable premature truncated protein products due to nonsense mutations or frameshift mutations resulting in loss of antibody recognition sites (24) . Also, overexpression of dominant inhibitors of p53 activity such as the mdm-2 protein, and binding to viral proteins such as the high-risk HPV16/18 E6 protein down-regulates p53 (36) . Recently, Saranath et al reported the presence of HPV16 in 25% of oral cavity tumors from India (6) . The interesting finding of the present study is that none of the female patients expressed nuclear p53 protein; however, at diagnosis all had advanced stage disease. In these women the role of HPV has to be studied. It has been shown that HPV in association with cmyc and p21ras might be playing a role in down-regulation of the p53 protein (37) . In our previous study, a significant positive association between c-myc and p21ras was also noted with down-regulation of p53 (38) . The reason for the notable variation in p53 positivity in the present study in comparison with other Indian studies may be due to variations in etiological factors (i.e., the use of different tobacco products with or without areca nut, lime and betal leaf). Also, the differences in the molecular profile between Indian chewing-tobacco-associated oral cancers and smoking-related cancers from the West have been reported earlier (39) (40) (41) .
Regarding the lack of association observed between p53 protein accumulation and clinicopathological parameters, these results are in agreement with many studies (14, 20, 27, 42) . Numerous studies including our own have demonstrated that p53 expression was higher in non-chewers than in chewers and in non-smokers than in smokers (29, 42, 43) . Therefore, the pathogenesis of tobacco-associated cancer might follow a p53-independent pathway, or multiple genetic alterations occurring due to the carcinogenic effect of tobacco down-regulate p53. Further, it will be interesting to study p53 protein expression and mutation in tobacco non-chewers with premalignant disease. In contrast, Field et al demonstrated an association between heavy smoking and drinking, and elevated p53 expression in patients with head and neck cancer (3). In the present study, univariate survival analysis showed no association with overall survival in the entire patient series and in patients grouped according to disease stage, as the p53 positivity was low. However, in a small group of early stage patients (n=18), 50% (2/4) of the patients with p53 expression relapsed within five years, while 21% (3/14) of the patients with negative p53 relapsed within five years. This would suggest that p53 expression is an early event in cell transformation in tobacco-associated tongue carcinoma. Shin et al (25) have shown nuclear accumulation of p53 while Pukkila et al (44) have shown nuclear and cytoplasmic overexpression of p53 associated with unfavorable disease outcome.
In conclusion, because a large number of patients with tongue hyperplasia and dysplasia expressed p53 aberrantly and there was a higher relapse rate in p53positive early stage tongue cancer, p53 accumulation is believed to be an early event in the neoplastic progression of disease in the tongue. p53 may thus play an important role in the initiation of tongue tumors. An effort to determine whether the p53 positivity observed in leukoplakia patients in the present study was a result of mutation or accumulation of normal p53 induced by tobacco carcinogens is under way.
